(Q38059008)

27 August 2017

title

Gene therapy for cardiovascular disease: perspectives and potential (English)

1 reference

27 August 2017

0 references

cardiovascular disease

1 reference

Angela C Bradshaw

1

1 reference

27 August 2017

Andrew H Baker

series ordinal

2

1 reference

27 August 2017

publication date

7 November 2012

1 reference

27 August 2017

published in

Vascular Pharmacology

1 reference

27 August 2017

volume

58

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

174-181

1 reference

Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

A Role for miR-145 in Pulmonary Arterial Hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Tropism-modification strategies for targeted gene delivery using adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Manipulation of adenovirus interactions with host factors for gene therapy applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Gene therapy clinical trials worldwide to 2007--an update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

CD46 is a cellular receptor for group B adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

The temporal relationship between the development of vein graft intimal hyperplasia and growth factor gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Trends in adult cardiovascular disease risk factors and their socio-economic patterning in the Scottish population 1995-2008: cross-sectional surveys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Established neointimal hyperplasia in vein grafts expands via TGF-beta-mediated progressive fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Atherosclerosis-like lesions of the aortic valve are common in adults of all ages: a necropsy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Downregulation of CD46 during muscle differentiation: implications for gene transfer to human skeletal muscle using group B adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

What does it take to bind CAR?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

MicroRNA-26a is a novel regulator of vascular smooth muscle cell function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Progress and challenges in translating the biology of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Combating hepatitis C virus by targeting microRNA-122 using locked nucleic acids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

In stent restenosis: bane of the stent era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

A new link between virus cell entry and inflammation: adenovirus interaction with integrins induces specific proinflammatory responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Matrix metalloproteinase inhibition therapy for vascular diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

The "STEP-wise" future of adenovirus-based HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Marimastat inhibits neointimal thickening in a model of human vein graft stenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Adenoviruses: update on structure and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

The Cell Adhesion Molecule “CAR” and Sialic Acid on Human Erythrocytes Influence Adenovirus In Vivo Biodistribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal-regulated kinases-1 and -2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Vascular remodeling and protease inhibition--bench to bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Atherosclerosis in the young: risk and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Extracellular control of TGFbeta signalling in vascular development and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Radial Artery Conduits Improve Long-Term Survival After Coronary Artery Bypass Grafting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Complement component C1q and anti-hexon antibody mediate adenovirus infection of a CAR-negative cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

TGF-beta through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Adenovirus serotype 5 hexon mediates liver gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Vein graft failure: current clinical practice and potential for gene therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Antisense to transforming growth factor-beta1 messenger RNA reduces vein graft intimal hyperplasia and monocyte chemotactic protein 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Transforming growth factor-beta1 antisense treatment of rat vein grafts reduces the accumulation of collagen and increases the accumulation of h-caldesmon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Development of efficient viral vectors selective for vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-OH kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.10.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VPH.2012.10.008

1 reference

27 August 2017

1 reference